KVUE Stock Recent News

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Just like trying to catch falling knives, chasing stocks can be a dangerous endeavor. In this update, I share my latest thoughts on Kenvue stock, focusing specifically on the Q2 2024 results that sent the stock soaring 25%. I've incorporated the latest results into my valuation model and explain what the market is currently pricing in for KVUE stock.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) is releasing its first Task Force on Climate-related Financial Disclosures (TCFD) report.

Kenvue Inc. KVUE — the parent company of well-known pharmacy items like Listerine, Mylanta, and Tylenol — is showing a bullish pattern on the charts Tuesday.

SKILLMAN, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) (“Kenvue”) today announced the Company's participation in the Barclays Global Consumer Staples Conference in Boston, Massachusetts. Thibaut Mongon, Chief Executive Officer, Paul Ruh, Chief Financial Officer, and Charmaine England, Chief Growth Officer, will participate in a fireside chat on Thursday, September 5, 2024, at 3:00 p.m. Eastern Time. A live webcast of the session will be available on investors.kenvue.com and a replay will be.

New Product Line Features Two Moisturizers Designed to Defend and Support the Skin's Natural Collagen SKILLMAN, N.J. , Aug. 15, 2024 /PRNewswire/ -- Kenvue Inc. (NYSE: KVUE) ("Kenvue" or the "Company"), the world's largest pure-play consumer health company by revenue, is launching Neutrogena®1 Collagen Bank™ featuring the Company's patented micro-peptide technology.

Kenvue's share price recently spiked as a result of a strong second quarter earnings report. Kenvue's strong brands continued to gain market shares, showing progress despite challenges in the consumer environment. Strong brand performance with growth in well-known products like Listerine, Tylenol, Zyrtec, and Benadryl.

Johnson & Johnson spun off its consumer segment into Kenvue, a $40 billion company in the consumer defensive sector. Kenvue operates in three main segments, including well-known brands like Tylenol, Neutrogena, and Listerine, with a global sales distribution. Despite recent underperformance, Kenvue saw a 14% stock price rally after reporting 2Q24 earnings, beating market expectations and showing signs of optimism.

Major U.S. equities indexes rebounded on Tuesday following three turbulent days of trading that saw heightened levels of economic uncertainty send stocks tumbling.